HDAC inhibitors are also reported to enhance ROS levels in melanomas 53 and other tumors 54, 55, 56, 57 by unknown mechanisms, but other studies report modest or no effects alone 58, or even reduced ROS after long‐term HDAC inhibitor treatment 59. This evidence concerns the gene HDAC9 and melanoma.